SCHEMBL19074591

SCHEMBL19074591

CC(=O)c1coc(C(C)(C)C(C)NC(=O)OC(C)(C)C)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.36
TRPA1 O75762 1/20 0.36
TSHR P16473 1/20 0.36
HSD17B10 Q99714 1/20 0.36
C3AR1 Q16581 2/20 0.36
CTSK P43235 1/20 0.35
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
CA7 P43166 2/20 0.35
MAPT P10636 2/20 0.34
KDM4E B2RXH2 1/20 0.34
GLA P06280 1/20 0.34
GAA P10253 1/20 0.34
HPGD P15428 1/20 0.34
ABCB1 P08183 2/20 0.34
EPHX2 P34913 1/20 0.33
LMNA P02545 1/20 0.33
CA4 P22748 1/20 0.33
CA9 Q16790 1/20 0.33
ATM Q13315 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12492378 0.89 CTSK (0.37) KMT2ATRPA1TSHRHSD17B10C3AR1
SCHEMBL12492379 0.89 CTSK (0.37) KMT2ATRPA1TSHRHSD17B10C3AR1
SCHEMBL12455889 0.72 HDAC1 (0.39) KMT2ACA1CA2MAPTGAA
SCHEMBL17281398 0.70 DAGLA (0.36) KDM4EALDH1A1
SCHEMBL12682253 0.70 DAGLA (0.35) MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL15214453 0.68 C3AR1 (0.43) KMT2ATRPA1TSHRHSD17B10C3AR1
SCHEMBL800492 0.68 KMT2A (0.49) KMT2ATRPA1TSHRHSD17B10C3AR1
SCHEMBL15214452 0.68 C3AR1 (0.40) KMT2ATRPA1TSHRHSD17B10C3AR1
SCHEMBL800494 0.68 KMT2A (0.48) KMT2ATRPA1TSHRHSD17B10C3AR1
SCHEMBL3511397 0.68 KMT2A (0.48) KMT2ATRPA1TSHRHSD17B10C3AR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2685982-B1 PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES BRISTOL MYERS SQUIBB CO (US) 2017-07-05 EP disclosed